JJDC — 2026 Investments

2 investments dated 2026 · listed companies and verified rows first · show all

Cellular Originscellularorigins.com inJan 2026

Cellular Origins provides automated cell therapy manufacturing solutions through its Constellation platform, which integrates robotics and digital management to enable GMP-compliant scaling of cell therapies with minimal process modification.

Advanced ManufacturingBiotechRoboticsCambridge, GB

Alex Lang(Founder)

Co-investorsHighland Europe NYBC Ventures Business Growth Fund Johnson & Johnson Innovation – JJDC

Mestagmestagtherapeutics.com in 𝕏Mar 2026 · $40M

Mestag is an immunology company developing first-in-class treatments for cancer and inflammatory diseases by leveraging novel understanding of fibroblast biology and tertiary lymphoid structures.

AI & Machine LearningBiotechDigital HealthHealthtechLondon, GB

Michael B. Brenner(Founder)Chris Buckley(Founder)Mark Coles(Founder)inSoumya Raychaudhuri(Founder)David A. Tuveson(Founder)Lindsey Rolfe(Chief Medical Officer)in

Co-investorsGV (Google Ventures)SV Health Investors Forbion Johnson & Johnson Innovation – JJDC Northpond Ventures

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.